Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Plasma Protein Therapeutics Market Worth US$ 31 Billion by 2024

Plasma Protein Therapeutics Market
Posted on: 10 Oct 16
Plasma Protein Therapeutics Market Worth US$ 31 Billion by 2024

Florida, October 10: Market Research Engine has published a new report titled as “Plasma Protein Therapeutics Market by Product Type (C1 esterase Inhibitors, Albumins, Immunoglobulin’s & Coagulation Factors), by Application Type (Hereditary Angioedema, Hemophilia, Primary Immunodeficiency Disorder) - Global Industry Analysis, Trends and Forecast 2016 - 2024”

The Plasma Protein Therapeutics Market is expected to exceed more than USD 31 Billion by 2024; Growing at a CAGR of more than 7.5% in the given forecast period.

Download Free Sample Report: https://www.marketresearchengine.com/requestsample/plasma-protein-therapeutics-market-report

Plasma is the liquid parts of blood that residue once platelets, white and red blood cells and various other cellular components are detached. In human blood only plasma is largest component and contains proteins, antibodies, enzymes, salts and water. Plasma is the protein rich fluids that defer cells in human blood and achieves various essential transport functions. The proteins that originate in plasma plays important function in clotting and provide immunity to diseases. Plasma proteins are used in many conditions for treatment such as shocks & burns, neurological & bleeding disorders, autoimmune and immune deficiencies.

Plasma protein therapies is a unique biological medicine which contains biological starting material called plasma which have unique bio chemical profile which differs in processing methods and production methods. Plasma protein therapies are used to treat various genetic, chronic, life threatening and rare diseases.

The plasma protein therapeutics market is segmented on the lines of its product type, application and regional. Under product type segmentation it covers C1 esterase inhibitors, albumins, immunoglobulin’s and coagulation factors. Based on application segmentation the plasma protein therapeutics covers hereditary angioedema, hemophilia, primary immune deficiency disorder, secondary immune deficiency, idiopathic thrombocytopenic and others such as Kawasaki disease, GBS, CIDP etc.The plasma protein therapeutics market's geographic segmentation covers various regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geographical region market is further segmented to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, India, Brazil, and GCC countries.

Browse Full Report here: https://www.marketresearchengine.com/reportdetails/plasma-protein-therapeutics-market-report

This report provides:

1) An overview of the global market for plasma protein therapeutics and related technologies.

2) Analyses of global market trends, with data from 2013, estimates for 2014 and 2015, and projections of compound annual growth rates (CAGRs) through 2020.

3) Identifications of new market opportunities and targeted promotional plans for plasma protein therapeutics.

4) Discussion of research and development, and the demand for new products and new applications.

5) Comprehensive company profiles of major players in the industry.

REPORT SCOPE:

The scope of the report includes a detailed study of global and regional markets .The reasons given for variations in the growth of the industry in certain regions.

The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global market. Key players profiled in the report include Baxter International, Biotest, CSL Behring, Grifols, S.A., Kedrion, Octapharma USA, Inc., Shire Plc. and China Biologics. CSL Behring is the market leader in the plasma protein therapeutics market, while GRIFOLS, S.A leads the global market for IVIG and Alpha 1 antitrypsin. Company profile includes assign such as company summary, financial summary, business strategy and planning, SWOT analysis and current developments.

The Top Companies Report is intended to provide our buyers with a snapshot of the industry’s most influential players.

The Plasma Protein Therapeutics Market has been segmented as below:  

By Product Type Analysis

C1 esterase Inhibitors
Albumins
Immunoglobulins
Coagulation Factors
Others

By Application Analysis

Hereditary Angioedema
Hemophilia
Primary Immunodeficiency Disorder
Secondary Immunodeficiency
Idiopathic Thrombocytopenic
Others (Kawasaki disease, GBS, CIDP etc)

By Regional Analysis

North America
Europe
Asia-Pacific
Rest of the World

For more information:
www.marketresearchengine.com

Editor's Details

John Bay
Market Research Engine
www.marketresearchengine.com
1-855-984-1862
john@marketresearchengine.com

Last updated on: 10/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.